James Chmiel, MD, MPH
Director and Chief Executive

James Chmiel has over 20 years of experience in the field of pediatric pulmonology and is currently the Clinical Director of Pediatric Pulmonology at the University Hospitals Rainbow Babies and Children’s Hospital. He has participated in both independent and multi-center clinical trials. Chmiel’s research involves understanding the inflammatory response of the lung, particularly as it relates to asthma and cystic fibrosis and the impact of anti-inflammatory therapeutics upon this response. The goal of his research is to develop safer and more effective anti-inflammatory therapeutics for the treatment of asthma and CF lung disease. Chmiel’s extensive knowledge of the health care and pharmaceutical industries is critical to his leadership of the OCTC.


John R. Peterson, PhD
Executive Director, Global Business Development

John Peterson is a seasoned leader in the pharmaceutical and chemical industries and a proven innovator in complex technology development and commercialization. His education is deeply rooted in the chemical sciences, from which he holds an impressive list of awards, peer-reviewed publications, and patents. His former industrial and academic appointments have included senior executive, intellectual property development, operations, science, and corporate development on a global scale. In addition, Peterson is registered to practice patent law before the U.S. Patent and Trademark Organization.


Joseph Peter, BSBA, MA, MBA, PMP
Manager, Network Operations

Joseph Peter began his career in engineering and manufacturing software. He held positions of increasing authority to include Information Technology operations for a two billion dollar manufacturing company which later transitioned into leading large scale complex software development projects in the financial industry. Recently he successfully led and completed the CWRU Regional Extension Center/HiTech Grant, resulting in a high adoption of electronic health records and achievement of meaningful use in Cleveland as well as in several nearby counties.


Kate Hilliard, BA, CCRC
Manager, Clinical Trials Operations

Kate Hilliard’s career began in industry as a preclinical toxicologist, in the Pharmacology and Drug Development Section at the Battelle Memorial Institute in Columbus, Ohio. Over the past 20 years, she has developed expertise in the area of cystic fibrosis through the coordination of industry and government sponsored clinical studies, as well as the management of regulatory affairs and operations. Hilliard has served on several national committees for the CF Therapeutics Development Network and has developed a national research coordinator mentoring program, for which she has won an award recognizing research coordinator excellence. Hilliard is currently the Director of Clinical Research Operations for the Department of Pediatrics where she manages clinical research operations in the Division of Pediatric Pulmonology and Allergy/Immunology at the University Hospitals Rainbow Babies and Children’s Clinical Research Center.